Clinical Trials
112 trialsNCT05571969 2026-06-01
Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Terminated
NCT05839600 2026-05-22
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT04158141 2026-05-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT05582850 2026-05-12
EPRAD
Domain Therapeutics SA
Phase 1 Terminated
NCT04668833 2026-05-07
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT05147272 2025-12-05
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT03770494 2025-11-04
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05976334 2025-10-06
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
Phase 1 Terminated
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04455620 2025-07-02
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
BioNTech SE
Phase 1/2 Terminated
NCT04671901 2025-05-28
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT04642365 2025-05-21
A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
Hoffmann-La Roche
Phase 1 Terminated
NCT04171219 2025-05-16
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04827576 2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2 Terminated
NCT05435339 2025-04-22
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
Genmab
Phase 1/2 Terminated
NCT04084366 2025-03-26
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
OBI Pharma, Inc
Phase 1/2 Terminated
NCT04074759 2025-01-23
FPT155-001
Five Prime Therapeutics, Inc.
Phase 1 Terminated
NCT03854227 2025-01-13
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
Pfizer
Phase 1 Terminated
NCT05382936 2025-01-09
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
Phase 1 Terminated
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT05394350 2024-11-08
MK-1088-002
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT03379259 2024-10-26
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
Phase 1/2 Terminated
NCT01127178 2024-10-10
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Terminated
NCT02994953 2024-09-20
COMBO
EMD Serono
Phase 1 Terminated
NCT04747470 2024-09-03
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Terminated
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT04957290 2024-06-18
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Noxopharm Limited
Phase 1/2 Terminated
NCT04488003 2024-06-04
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT03319537 2024-05-23
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04430348 2024-03-12
PTX-35 in Patients With Advanced Solid Tumors
Heat Biologics
Phase 1 Terminated
NCT04158583 2024-03-04
A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT03461952 2024-02-22
NIMBLe
Canadian Cancer Trials Group
Phase 2 Terminated
NCT03573544 2024-02-22
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
OBI Pharma, Inc
Phase 1/2 Terminated
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT03834220 2024-02-07
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Debiopharm International SA
Phase 2 Terminated
NCT04071756 2024-02-07
Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
Dana-Farber Cancer Institute
Phase 2 Terminated